SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 30303044.
  • 2
    U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2004 Incidence and Mortality Web-Based Report. Bethesda, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007. Available at: www.cdc.gov/uscs. Accessed on July 15, 2008.
  • 3
    Madeleine MM,Daling JR. Cancers of the vulva and vagina. In: ShottenfeldD,FraumeniJF, eds. Cancer Epidemiology and Prevention.3rd ed. New York: Oxford University Press; 2006: 10681074.
  • 4
    Schiffman M,Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;( 31): 1419.
  • 5
    Srodon M,Stoler MH,Baber GB,Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006; 30: 15131518.
  • 6
    Cogliano V. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomavirus [90]. Lyon, France: International Agency for Research on Cancer; 2007.
  • 7
    Hoots B,Kurman R,Smith JS. Human papillomavirus type distribution in vaginal and vulvar cancers and their precursors: a meta-analysis. Presented at the International Papillomavirus Virus Conference, Beijing, China, November 2007.
  • 8
    Hampl M,Sarajuuri H,Wentzensen N,Bender HG,Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol. 2006; 108: 13611368.
  • 9
    Judson PL,Habermann EB,Baxter NN,Durham SB,Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006; 107: 10181022.
  • 10
    Watson M,Saraiya M,Ahmed F, et al. U sing population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methdos. Cancer. 2008; 113( 10 suppl): 28412854.
  • 11
    Kurman RJ,Toki T,Schiffman MH. Basaloid and warty carcinomas of the vulva. Distinctive types of squamous cell carcinoma frequently associated with human papillomaviruses. Am J Surg Pathol. 1993; 17: 133145.
  • 12
    Madeleine MM,Daling JR,Carter JJ, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst. 1997; 89: 15161523.
  • 13
    Brinton LA,Nasca PC,Mallin K,Baptiste MS,Wilbanks GD,Richart RM. Case-control study of cancer of the vulva. Obstet Gynecol. 1990; 75: 859866.
  • 14
    Daling JR,Sherman KJ,Hislop TG, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol. 1992; 135: 180189.
  • 15
    Frisch M,Goodman MT. Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S. Cancer. 2000; 88: 14641469.
  • 16
    Chaturvedi AK,Engels EA,Gilbert ES, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007; 99: 16341643.
  • 17
    Balamurugan A,Ahmed F,Saraiya M, et al. Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors. Cancer. 2008; 113( 10 suppl): 29192925.
  • 18
    Kleinerman R,Kosary CL,Hildesheim A. New malignancies following cancer of the cervix uteri, vagina, and vulva. In: CurtisRE,FreedmanDM,RiesLAG, et al, eds. New Malignancies Among Cancer Survivors. NIH Pub. No. 05-5302. SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006: 207229
  • 19
    Sideri M,Jones RW,Wilkinson EJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005; 50: 807810.
  • 20
    Scurry J,Wilkinson EJ. Review of terminology of precursors of vulvar squamous cell carcinoma. J Low Genit Tract Dis. 2006; 10: 161169.
  • 21
    Markowitz LE,Dunne EF,Saraiya M,Lawson HW,Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 124.
  • 22
    Joura EA,Leodolter S,Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of 3 randomised clinical trials. Lancet. 2007; 369: 16931702.